CAS: 193954-28-8; Fmoc-B-Hophe-Oh

相似化合物

138165-77-2 120378-17-8 101555-61-7

上下游产品

CAS号172097-41-5 N-[(1S)-3-重氮基-2... | CAS号35661-40-6 Fm°C-L-苯丙氨酸 | CAS号82911-69-1 9-芴甲基-N-琥珀酰亚胺碳酸酯 | CAS号114645-20-4 (S)-3-amino-4-p... | CAS号103321-57-9 N-(9-芴甲氧羰基)苯丙氨酰氯 | CAS号4425-82-5 9-亚甲基-9H-芴 | CAS号15099-85-1 (±)-3-氨基-4-苯基丁酸

Fmoc-L-苯丙氨酸置于n-甲基吗啉,Silver Trifluoroacetate,三乙胺,氯甲酸异丁酯体系中,用 四氢呋喃,水 用作溶剂,化学反应 4.33H,反应生成Fmoc-L-Beta-高苯丙氨酸
参考文献:的制备ñ-Fmoc保护的β 2-和β3氨基酸和它们作为构建块的β肽固相合成中的用途†往最‡
标题:的制备ñ-Fmoc保护的β 2-和β3氨基酸和它们作为构建块的β肽固相合成中的用途†往最‡
摘要:受n-Fmoc保护的(fmoc =(9 H-氟-9-基甲氧基)羰基)β-氨基酸是在固相支持物上高效合成β-寡肽所必需的.对映体纯的fmoc-β 3-氨基酸β 3:侧链和nh 2在c(3)(= C(β))从fmoc保护的(制备小号)-和(-[r)-α-氨基酸与脂族,芳香族和官能化侧链,使用标准或优化的arndt-Eistert反应顺序.将fmoc-β 2-氨基酸(β 2在c(2),Nh侧链2(中c 3)(= C(β)))配置轴承丙氨酸,缬氨酸,亮氨酸,和phe的侧链合成经由所述埃文斯'手性助剂的方法.目标β 3个-Heptapeptides 5-8,一个β 3-十五肽9和β 2-Heptapeptide 10使用常规的固相肽合成方法(在手动固相合成装置合成方案3).在β的情况下3-肽,两种方法被用于锚定所述第一β氨基酸:酯化的邻-Chlorotrityl氯乙烯树脂与所述第一的
Doi:10.1002/hlca.19980810202

专利信息

专利号:US-2020149034-A1
优先权日:2017-03-17
标题:Methods and Compositions for Synthesis of Encoded Libraries

专利号:US-8338565-B2
优先权日:2008-08-20
标 题 :Macrocyclic compounds for inhibition of tumor necrosis factor alpha
发明人：LEE JINBO; BOND JULIAN F; TERRETT NICHOLAS; FAVALORO JR FRANK G; WANG DANIEL; BRIGGS TIMOTHY F; SEIGAL BENJAMIN ADAM; SUN WEI-CHUAN; HALE STEPHEN P
权利人:LEE JINBO; BOND JULIAN F; TERRETT NICHOLAS; FAVALORO JR FRANK G; WANG DANIEL; BRIGGS TIMOTHY F; SEIGAL BENJAMIN ADAM; SUN WEI-CHUAN; HALE STEPHEN P; ENSEMBLE THERAPEUTICS CORP
摘要:Disclosed herein are macrocyclic compounds and methods for their synthesis and use. In particular, macrocyclic compounds are disclosed that modulate the activity of tumor necrosis factor alpha and/or are useful in the treatment of medical conditions, such as, rheumatoid arthritis, psoriasis, and asthma.

专利号:US-10017481-B2
优先权日:2012-03-17
标 题 :Conformationally constrained, fully synthetic macrocyclic compounds
发明人：OBRECHT DANIEL; ERMERT PHILIPP; OUMOUCH SAID; PIETTRE ARNAUD; GOSALBES JEAN-FRANÇOIS; THOMMEN MARC
权利人:POLYPHOR AG
摘要:The conformationally restricted, spatially defined macrocyclic ring system of formula (I) is constituted by three distinct molecular parts: Template A, conformation Modulator B and Bridge C. Macrocycles described by this ring system I are readily manufactured by parallel synthesis or combinatorial chemistry in solution or on solid phase. They are designed to interact with a variety of specific biological target classes, examples being agonistic or antagonistic activity on G-protein coupled receptors (GPCRs), inhibitory activity on enzymes or antimicrobial activity. In particular, these macrocycles show inhibitory activity on endothelin converting enzyme of subtype 1 (ECE-1) and/or the cysteine protease cathepsin S (CatS), and/or act as antagonists of the oxytocin (OT) receptor, thyrotropin-releasing hormone (TRH) receptor and/or leukotriene B4 (LTB4) receptor, and/or as agonists of the bombesin 3 (BB3) receptor, and/or show antimicrobial activity against at least one bacterial strain. Thus they are showing great potential as medicaments for a variety of diseases.